Updated Review of Nuclear Molecular Imaging of Thyroid Cancers

被引：11
作者：
Fu, Hao [1 ,2 ]
Sa, Ri [1 ,3 ]
Cheng, Lin [1 ]
Jin, Yuchen [1 ]
Qiu, Xian [1 ]
Liu, Min [1 ,4 ]
Chen, Libo [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Dept Nucl Med, Affiliated Peoples Hosp 6, Yishan Rd 600, Shanghai 200233, Peoples R China
[2] Fujian Med Univ, Dept Nucl Med, Teaching Hosp, Xiamen Univ,Affiliated Hosp 1,Xiamen Canc Hosp, Xiamen, Peoples R China
[3] First Hosp Jilin Univ, Dept Nucl Med, Changchun, Peoples R China
[4] Fudan Univ, Zhongshan Hosp, Dept Nucl Med, Shanghai, Peoples R China
来源：
ENDOCRINE PRACTICE | 2021年 / 27卷 / 05期
基金：
中国国家自然科学基金;
关键词：
nuclear molecular imaging; thyroid cancer; nuclear medicine; radiopharmaceuticals; POSITRON-EMISSION-TOMOGRAPHY; PREABLATION 131-I SCANS; WHOLE-BODY SCAN; I-124; PET/CT; F-18-FDG PET; FOLLOW-UP; ASSOCIATION GUIDELINES; INCREASED CALCITONIN; SERUM THYROGLOBULIN; COMPUTED-TOMOGRAPHY;
D O I：
10.1016/j.eprac.2020.10.001
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Objectives: We initiate this comprehensive review to update the advances in this field by objectively elucidating the efficacies of promising radiopharmaceuticals. Methods: We performed a comprehensive PUBMED search using the combined terms of "thyroid cancer" and "radiopharmaceuticals" or "nuclear medicine", yielding 3273 and 11026 articles prior to December 31, 2020, respectively. Results: Based on the mechanism of molecular metabolism, the evaluation of differentiated thyroid cancer and dedifferentiated thyroid cancer is largely centered around radioiodine and fluorine 18 (F-18)-fludeoxyglucose, respectively. Further, F-18-L-dihydroxyphenylalanine and gallium 68 DOTATATE are the preferred tracers for medullary thyroid cancer. In dedifferentiated medullary thyroid cancer and anaplastic thyroid cancer, F-18-fludeoxyglucose is superior. Conclusions: The future lies in advances in molecular biology, novel radiopharmaceuticals and imaging devices, paving ways to the development of personalized medication for thyroid cancer patients. (C) 2020 AACE. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码：494 / 502
页数：9
相关论文
共 99 条
[91]   Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma [J].
Treglia, Giorgio ;
Castaldi, Paola ;
Villani, Maria Felicia ;
Perotti, Germano ;
de Waure, Chiara ;
Filice, Angelina ;
Ambrosini, Valentina ;
Cremonini, Nadia ;
Santimaria, Monica ;
Versari, Annibale ;
Fanti, Stefano ;
Giordano, Alessandro ;
Rufini, Vittoria .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 (04) :569-580
[92]   Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in the Identification of Metastasis in Differentiated Thyroid Cancer with 131I Planar Whole-Body Imaging and 124I PET [J].
Van Nostrand, Douglas ;
Khorjekar, Gauri R. ;
O'Neil, Jeff ;
Moreau, Shari ;
Atkins, Frank B. ;
Kharazi, Pejman ;
Mete, Mihriye ;
Chennupati, Shyam P. ;
Burman, Kenneth D. ;
Wartofsky, Leonard .
JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (03) :359-362
[93]   124I Positron Emission Tomography Versus 131I Planar Imaging in the Identification of Residual Thyroid Tissue and/or Metastasis in Patients Who Have Well-Differentiated Thyroid Cancer [J].
Van Nostrand, Douglas ;
Moreau, Shari ;
Bandaru, Varalakshmi V. ;
Atkins, Frank ;
Chennupati, Shyam ;
Mete, Mihriye ;
Burman, Kenneth ;
Wartofsky, Leonard .
THYROID, 2010, 20 (08) :879-883
[94]   Clinical Relevance of 18F-FDG PET and 18F-DOPA PET in Recurrent Medullary Thyroid Carcinoma [J].
Verbeek, Hans H. G. ;
Plukker, John T. M. ;
Koopmans, Klaas Pieter ;
de Groot, Jan Willem B. ;
Hofstra, Robert M. W. ;
Kobold, Anneke C. Muller ;
van der Horst-Schrivers, Anouk N. A. ;
Brouwers, Adrienne H. ;
Links, Thera P. .
JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (12) :1863-1871
[95]   Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT [J].
Verma, Priyanka ;
Malhotra, Gaurav ;
Agrawal, Ritesh ;
Sonavane, Sunita ;
Meshram, Vilas ;
Asopa, Ramesh V. .
CLINICAL NUCLEAR MEDICINE, 2018, 43 (08) :E265-E268
[96]  
Wangberg, 1997, Oncologist, V2, P50
[97]   Dose-Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT [J].
Wierts, Roel ;
Brans, Boudewijn ;
Havekes, Bas ;
Kemerink, Gerrit J. ;
Halders, Servais G. ;
Schaper, Nicolaas N. ;
Backes, Walter H. ;
Mottaghy, Felix M. ;
Jentzen, Walter .
JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (07) :1027-1032
[98]   No Adverse Affect in Clinical Outcome Using Low Preablation Diagnostic 131I Activity in Differentiated Thyroid Cancer: Refuting Thyroid-Stunning Effect [J].
Yap, Beng Khiong ;
Murby, Brian .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (07) :2433-2440
[99]   Integrin αvβ3 Imaging of Radioactive Iodine-Refractory Thyroid Cancer Using 99mTc-3PRGD2 [J].
Zhao, Dan ;
Jin, Xiaona ;
Li, Fang ;
Liang, Jun ;
Lin, Yansong .
JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (12) :1872-1877
12345678910